Advertisement|Remove ads.

ImmunityBio, Inc. (IBRX) announced on Thursday that it expects a first-quarter net product revenue to reach approximately $44.2 million, marking a 168% year-on-year surge.
This performance builds on 2025 full-year net product revenue of $113 million, a 700% jump from 2024, and represents a 15% sequential increase over fourth-quarter 2025’s $38.3 million.
The company also highlighted that ANKTIVA, the interleukin-15-based immunotherapy, now holds approval or authorization in five regulatory jurisdictions, covering roughly 34 countries.
ImmunityBio stock edged 0.1% lower in Thursday’s premarket.
Get updates to this developing story directly on Stocktwits.